Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
US FDA Performance Tracker Drug Review Drug Approval Standards

Keeping Track: Recent NDA Submissions Range From Acute Agitation To Von Hippel-Lindau Disease

  • News

Executive Summary

News and highlights of applications submitted for US FDA approval, from the Pink Sheet’s FDA Performance Tracker

You may also be interested in...



Keeping Track: Vijoice, Igalmi Approvals Show New Faces Of Older Drugs; Facility Change Extends Vutrisiran Goal

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Keeping Track: Immunocore Wins Nod For First T-Cell Receptor Therapeutic; Veklury And Nucala Expand Settings Of Use; Merck & Co. Strikes Out In Chronic Cough

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Bad Times For Breakthrough Drugs Targeting Chemo Complications; Submissions From BMS, Merck

The latest news about applications under FDA review, from the Pink Sheet’s US FDA Performance Tracker

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Scrip
Pink Sheet
Scrip
Scrip
Scrip

Topics

Related Companies

Tags:
US FDA Performance Tracker Drug Review Drug Approval Standards
Latest Headlines

US FDA’s Marks Willing To Accept Gene Therapies Occasionally Not Confirming Benefit

FDA Is ‘Getting More Aggressive’ In Going After Drug Efficacy Claims Outside Label

BIO’s New CEO Is Biotech Industry Veteran With Compelling Family Story, Ready To Take On The IRA

Patient-Focused Listening Sessions For Medicare-Negotiated Drugs: Key Takeaways From Round One

See All
UsernamePublicRestriction

Register

PS144012

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By